Edward A. Motea
Biochemistry, Genetics and Molecular Biology · Indiana University
DNA Repair MechanismsPARP inhibition in cancer therapyCancer therapeutics and mechanismsBioactive Compounds and Antitumor AgentsDNA and Nucleic Acid Chemistry
Publications
51
Citations
1,019
Est. group size
—
Recurring co-author estimate
Active years
17
Publishing since 2008
Publication cadence
Publications per year over the last 10 years — averaging 3.6/year recently
Recent publications
- Abstract 5943: Development of a <i>SMART</i> theranostic agent for precision pancreatic cancer therapeutics
Cancer Research · 2024
- Supplementary Information from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Supplemental Information from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Table S1A-D from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplementary Information from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Data from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Data from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Data from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Data from NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers
2023
- Table S1A-D from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplemental Information from Kub5-Hera<i><sup>RPRD1B</sup></i> Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers
2023
- Supplementary Figure 1 from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Supplementary Figure 1 from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Data from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
- Data from Evaluating the Therapeutic Potential of a Non-Natural Nucleotide That Inhibits Human Ribonucleotide Reductase
2023
Publishes in
- The FASEB Journal×4
- PMC×3
- Clinical Cancer Research×2
- Cancer Cell×1
- PLoS Genetics×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile